

[Patients as Research Partners](#)



Integrated patient engagement model

CCTG uses an integrated patient engagement model that includes the patient voice in all aspects of cancer clinical trial development. Patients Representatives are not only involved in answering the scientific questions that clinical trials ask, they play an essential role on CCTG's national disease site committee as participating members who contribute to the development and delivery of the cancer research questions. Patient Representatives ensure that patient centred outcomes included in CCTG cancer clinical trials.

*Patient-oriented research refers to research that engages patients as partners, focuses on **patient-identified priorities** and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with stakeholders, aims to apply the knowledge generated to improve health care systems and practices. – msfhr.org - Michael Smith Foundation for Health Research*

Patient engagement in clinical trial research is two-fold:

1. Trial Participant – the human participant in the trial
2. Patient Representative – developing and delivering the research question, ensuring: patient feasibility, outcomes that matter to patients

There are several touch points where Patient Representatives provide input as members of Scientific, Oversight and Support Committees. They are actively involved at key junctures of the CCTG Clinical Trial life cycle: Development, Review/Approval, Protocol and Consent Development, Accrual and Data Collection and at the time of Permanent Closure.

THE PATIENT AS RESEARCH PARTNERS COMMITTEE REPRESENTATION

Patient Representatives are active committee members ensuring the patient voice is integrated across CCTG's trial development and over site structure.

SUPPORT COMMITTEE

Patient Representatives Committee

The role of the Patient Representatives is to provide the perspective of patients and their families, in the development and delivery of clinical trials at CCTG.



SCIENTIFIC COMMITTEES

Disease site committees & working groups
Brain, breast, lung, gastro-intestinal, genito-urinary, gynecologic, hematologic, melanoma, sarcoma, symptom control, head and neck.

Investigational New Drugs
Identifying newly-developed drugs with the potential to test for benefits to patients.

Endpoint

Economic Analysis, Correlative Sciences & Tumour Bank, Quality of Life.



OVERSIGHT COMMITTEES

Clinical Trials

Advising on all substantial issues concerning the CCTG clinical trials programme.

Data Safety Monitoring

Supervising CCTG quality assurance and quality control programs.

Strategic Executive Advisory

The primary strategic advisory body providing advice on overall CCTG policy and direction, as well as priorities and activities.

